These findings have provided valuable insights into the management of T2D and informed clinical practice guidelines and regulatory decisions.GLP-1 receptor agonists have emerged as an important therapeutic option for individuals with T2D, particularly those at high risk of CVD. Here, GLP1R is linked to type 2 diabetes mellitus.